Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

Next Previous
Search
Trial Profile

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LITESPARK-005
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 17 Feb 2025 Planned End Date changed from 17 Sep 2025 to 17 Sep 2026.
    • 27 Jan 2025 According to a Merck Sharp & Dohme media release, based on result from this trial the company received WELIREG approval in Canada for the treatment of adult patients with advanced RCC following a PD-1/PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
    • 13 Dec 2024 According to a Merck & Co Media Release, based on results from this trial the EMA's CHMP has adopted a positive opinion recommending the conditional approval of WELIREG, for the treatment of adult patients with advanced RCC that progressed following two or more lines of therapy that included a programmed death receptor-1 or PDL-1 inhibitor and at least two vascular endothelial growth factor targeted therapies. The final EU decision is expected in first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top